transfusion-associated graft-versus-host disease
Also found in: Acronyms, Wikipedia.
transfusion-associated graft-versus-host disease
Immunology A type of GVHD in which immunocompetent T cells administered during a transfusion to a recipient and attack the recipient's immune system Risk factors Poorly defined; may include BM graft recipients and Pts immunocompromised by chemotherapy or malignancy Clinical Fever,
skin rash, diarrhea, liver dysfunction–abnormal LFTs, severe pancytopenia Prevention Gamma irradiation of blood products with 15-25 Gy–1500–2500 rad; up to 50 Gy can be used for most blood products; the onset of TAGVHD is early–10-12 days, often accompanied by BM aplasia, poor response to immunosuppression, postoperative erythroderma, 90% mortalityMcGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive
A systematic review of transfusion-associated graft-versus-host disease. Blood.
Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease? Transfusion.
Transfusion-associated graft-versus-host disease (TA-GVHD) is an uncommon yet highly fatal complication of cellular blood product transfusion including red blood cell, platelet, and granulocyte products.
Copyright © 2003-2025 Farlex, Inc
Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.